secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAge Labs, Inc. (BIOA)
CIK:        0001709941
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0000950170-25-104151
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAge Labs Q2 net loss $21.6M, cash $313.4M; BGE-102 Phase 1 on track for 2H 2025
--------------------------------------------------------------------------------

- Net loss $21.6M ($0.60/share) vs $13.6M loss in Q2 2024; R&D expenses rose to $19.8M.
- Cash and marketable securities $313.4M as of June 30, 2025; runway through 2029.
- BGE-102 IND-enabling completed; Phase 1 SAD/MAD starts 2H 2025 with data by year-end.
- Option agreement for APJ agonist nanobody with >10x apelin potency; oral APJ patent filed.
- Launched HUNT Biobank collaboration to profile 17,000+ samples for aging biology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1709941/000095017025104151/0000950170-25-104151-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1709941/000095017025104151/bioa-20250806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104151

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer